Investigating the RAL GTPases as novel targets for the treatment of RASMT CRC
School of Medicine, Dentistry and Biomedical Sciences
- Location
- Belfast, United Kingdom
- Funding
- See university guidance
- Application deadline
- See university guidance
About the project
RAS and BRAF mutated (MT) colorectal cancers (CRC) occur in >60% of CRC patients and are associated with poor outcome. Although the therapeutic armamentarium of CRC has increased over the last 2 decades, there are subgroups of RAS and BRAFMT CRC in urgent need for novel treatments.
The research is focused on the identification of novel targets and pathways that are particularly relevant to drug resistance in the context of RAS/BRAFMT at the bench and applying this at the bedside.
- Dr Sandra Van Schaeybroeck: School of Medicine, Dentistry and Biomedical Sciences
Contact info
- View Academic Profile
- askmhls@qub.ac.uk
- +44 (0)28 9097 2954
Research Interests
Open to PhD applications in the field of
Make a PhD enquiry
- Laboratory based investigations into molecular mechanisms including altered pro-survival signaling pathways in RASMT and BRAFMT CRC
- Discovery of novel resistance mechanisms to therapy mechanisms in RASMT and BRAFMT CRC
- Innovative biomarker development using samples from RASMT and BRAFMT CRC patients
Public outreach & key achievements
- Queen's University Belfast in bowel cancer discovery
Research students
PhD Title | Investigating the RAL GTPases as novel targets for the treatment of RASMT CRC
Country | Pakistan
PhD Title | Oncogenic deregulation of epithelial apical biogenesis as a unifying mechanism for colorectal cancer (CRC) morphological heterogeneity
Country | Northern Ireland
Discover More
- Faculty of Medicine, Health and Life Sciences
- School of Medicine, Dentistry and Biomedical Sciences
- The Patrick G Johnston Centre for Cancer Research
- Gastro-Intestinal Cancer Research Group